Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
Create a narrative
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Novo Nordisk
BA
bactrian
Community Contributor
A Quality Compounder Marked Down on Overblown Fears
Novo Nordisk , a global leader in diabetes and obesity treatments, is trading at a deep discount to both its historical multiples and intrinsic value. The ADR is now priced at $47.05 , reflecting a normalized P/E ratio of just 13.4× , down from a five-year average closer to 25–30×.
View narrative
US$120.72
FV
62.4% undervalued
intrinsic discount
15.71%
Revenue growth p.a.
Set Fair Value
20
users have liked this narrative
6
users have commented on this narrative
49
users have followed this narrative
New
narrative
ASML Holding
IN
Investingwilly
Community Contributor
Why Now is the Time to buy ASML
What Does ASML Do? ASML Holding N.V. is a Dutch company and the world’s only supplier of extreme ultraviolet (EUV) lithography machines —a critical technology used to produce the world’s most advanced computer chips.
View narrative
US$1.00k
FV
30.9% undervalued
intrinsic discount
15.17%
Revenue growth p.a.
Set Fair Value
28
users have liked this narrative
5
users have commented on this narrative
77
users have followed this narrative
New
narrative
Wyndham Hotels & Resorts
ZW
Zwfis
Community Contributor
Wyndham Continues Global Expansion with 19% Ancillary Revenue Growth
WH is a company that I actually took interest in a couple of months ago when I happened to stay at one of their franchise hotels. I had to leave early in the morning at like 4 and when I went out to the parking lot I was astounded that in the little town I was was absolutely full.
View narrative
US$105.80
FV
19.2% undervalued
intrinsic discount
13.23%
Revenue growth p.a.
Set Fair Value
7
users have liked this narrative
2
users have commented on this narrative
10
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
UniCredit
AN
AnalystLowTarget
Consensus Narrative from 15 Analysts
Rising Fintech Disruption And Tighter Regulation Will Hamper Profitability
Key Takeaways Digital disruption and regulatory burdens threaten profitability, while underinvestment in technology risks loss of customers and increased operational costs. Heavy reliance on Southern Europe exposes UniCredit to regional economic shocks, leading to instability in earnings and heightened risk.
View narrative
€43.56
FV
48.6% overvalued
intrinsic discount
-1.08%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
14 days ago
author updated this narrative
Tate & Lyle
AN
AnalystHighTarget
Consensus Narrative from 11 Analysts
Rising Health Trends And Urbanization Will Expand Specialty Markets
Key Takeaways Synergy gains, innovation-driven specialty revenue growth, and superior solution-selling could significantly boost margins, operating leverage, and earnings beyond current expectations. Expansion in emerging markets and rising global demand for healthier food ingredients position Tate & Lyle for long-term revenue gains and increased pricing power.
View narrative
UK£9.00
FV
40.0% undervalued
intrinsic discount
12.14%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
14 days ago
author updated this narrative
Lynas Rare Earths
AN
AnalystHighTarget
Consensus Narrative from 14 Analysts
Global Electrification And Renewables Will Boost US And Malaysian Capacity
Key Takeaways Leadership in supply chain security and ESG compliance positions Lynas for outsized government support, premium pricing, and long-term contracts with stable earnings. Accelerated expansion, technical advantages, and surging ex-China demand create opportunities for rapid revenue growth and durable margin expansion.
View narrative
AU$13.48
FV
11.7% undervalued
intrinsic discount
51.72%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
14 days ago
author updated this narrative
Dr. Ing. h.c. F. Porsche
AN
AnalystLowTarget
Consensus Narrative from 18 Analysts
Accelerating Decarbonization Mandates And Geopolitical Tensions Will Squeeze Margins
Key Takeaways Accelerating regulations, market shifts, and urbanization are eroding demand for luxury vehicles, increasing compliance costs, and pressuring Porsche's long-term growth and profitability. Aggressive electrification and heavy competition risk brand dilution, unstable foreign markets, and persistent margin erosion, threatening Porsche's pricing power and earnings sustainability.
View narrative
€37.00
FV
20.8% overvalued
intrinsic discount
-1.10%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
14 days ago
author updated this narrative
Mr Price Group
AN
AnalystHighTarget
Consensus Narrative from 8 Analysts
African Urbanization And E-Commerce Will Expand Affordable Retail
Key Takeaways Strong market share gains and margin expansion, driven by digital investments and category innovation, position the company for sustained outperformance and higher earnings growth. Expansion into new segments and Africa's growing middle class unlocks unique top-line growth potential and enhances long-term shareholder value.
View narrative
R511.29
FV
59.4% undervalued
intrinsic discount
10.52%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
14 days ago
author updated this narrative
Holcim
AN
AnalystLowTarget
Consensus Narrative from 16 Analysts
Rising Regulatory Costs And Tech Disruption Will Undercut Legacy Operations
Key Takeaways Holcim faces rising costs and shrinking margins from climate regulations, technology upgrades, and aggressive sustainability investments that may not yield proportional returns. Slow adaptation to disruptive construction technologies and materials, alongside fierce local competition, threatens Holcim's market share and sustained revenue growth.
View narrative
CHF 49.47
FV
35.5% overvalued
intrinsic discount
-15.36%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
14 days ago
author updated this narrative
Getinge
AN
AnalystHighTarget
Consensus Narrative from 9 Analysts
Aging Populations, Digital Health And Emerging Markets Will Spur Lifesaving Demand
Key Takeaways Faster-than-expected scaling of new assets and recurring, high-margin products could significantly drive profitability above analyst expectations. Market exits by competitors, innovation, and emerging market investments position the company for outsized growth and a strong competitive advantage.
View narrative
SEK 300.00
FV
36.2% undervalued
intrinsic discount
6.35%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
14 days ago
author updated this narrative
Hong Kong Exchanges and Clearing
AN
AnalystLowTarget
Consensus Narrative from 14 Analysts
Diverging Chinese And Western Regulations Will Dampen Cross-Border Listings
Key Takeaways Intensifying competition, regulatory fragmentation, and the maturation of China's domestic markets are undermining HKEX's position as a premier listing venue. Shifts to decentralized finance and private capital markets threaten core revenue streams by reducing trading volumes and curtailing long-term growth opportunities.
View narrative
HK$325.00
FV
31.8% overvalued
intrinsic discount
2.89%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
14 days ago
author updated this narrative
Daiichi Sankyo Company
AN
AnalystLowTarget
Consensus Narrative from 17 Analysts
European Pressures Will Challenge The Oncology Pipeline While Alliances Cushion
Key Takeaways Heavy reliance on a few oncology products and patent risks could lead to abrupt revenue volatility if key assets face setbacks or biosimilar competition. High R&D and profit-sharing expenses may suppress profitability despite strong pipeline growth, while global pricing pressures and trade uncertainties threaten margins.
View narrative
JP¥4.50k
FV
18.7% undervalued
intrinsic discount
6.08%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
14 days ago
author updated this narrative
Value any company in seconds
Popular companies